Evidence mapPaperPMID 40167762Full record

ReviewCancer immunology, immunotherapy : CII2025

A new era of cancer immunotherapy: vaccines and miRNAs.

Gitika Sareen, Maneesh Mohan, Ashi Mannan, Kamal Dua, Thakur Gurjeet Singh

Abstract readReview
In one paragraph

Review in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. MicroRNA‑885‑5p regulates cell cycle progression in liver cancer cells.International journal of molecular medicine · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gitika Sareen *Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, India.
Maneesh Mohan *Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, India.
Ashi MannanChitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, India.
Kamal DuaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia. Kamal.Dua@uts.edu.au.
Thakur Gurjeet SinghChitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, India. gurjeet.singh@chitkara.edu.in.ORCID http://orcid.org/0000-0003-2979-1590

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer immunotherapy has transformed the treatment landscape, introducing new strategies to fight various types of cancer. This review examines the important role of vaccines in cancer therapy, focusing on recent advancements such as dendritic cell vaccines, mRNA vaccines, and viral vector-based approaches. The relationship between cancer and the immune system highlights the importance of vaccines as therapeutic tools. The discussion covers tumor cell and dendritic cell vaccines, protein/peptide vaccines, and nucleic acid vaccines (including DNA, RNA, or viral vector-based), with a focus on their effectiveness and underlying mechanisms. Combination therapies that pair vaccines with immune checkpoint inhibitors, TIL therapy, and TCR/CAR-T cell therapy show promising potential, boosting antitumor responses. Additionally, the review explores the regulatory functions of microRNAs (miRNAs) in cancer development and suppression, featuring miR-21, miR-155, the let-7 family, and the miR-200 family, among others. These miRNAs influence various pathways, such as PI3K/AKT, NF-κB, and EMT regulation, providing insights into biomarker-driven therapeutic strategies. Overall, this work offers a thorough overview of vaccines in oncology and the integrative role of miRNAs, setting the stage for the next generation of cancer immunotherapies.

Indexed as

Cancer VaccinesImmunotherapyMicroRNAsNeoplasmsAnimalsHumansCancer VaccinesMicroRNAsCancer vaccinesCombination therapyImmunotherapyMicroRNAs (miRNAs)Tumor immunogenicity

Identifiers

PMID40167762
PMCPMC11961864

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.